Glepaglutide
Also known as: Zeydovio, ZP1848
A long-acting GLP-2 analog for short bowel syndrome. Not FDA-approved; recommended for EU approval (Zeydovio) in September 2026.
Last updated
Mechanism of Action
Glepaglutide is a GLP-2 analog with a C-terminal lysine tail that forms a subcutaneous depot, releasing the drug slowly and producing active metabolites with a long effective half-life. It activates intestinal GLP-2 receptors, promoting mucosal growth, intestinal blood flow and absorption of fluid and nutrients. The slow release supports twice-weekly dosing from a ready-to-use injection.
- Half-life
- Long effective half-life from a subcutaneous depot; supports twice-weekly dosing
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Reduced weekly parenteral support volume with twice-weekly dosing in the EASE-1 Phase 3 trial
- Some trial participants were fully weaned from parenteral support
- Improved intestinal absorption of fluid in mechanistic studies
Potential Side Effects
- Injection-site reactions
- Abdominal pain and distension
- Nausea
- Peripheral edema and fluid shifts
Common Dosing
No FDA-approved dose. The EASE-1 trial and the EU application used 10 mg by subcutaneous injection twice weekly; a once-weekly arm did not meet the primary endpoint. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
No documented stacking partners for Glepaglutide yet.